Valuation: AC Immune SA

Market Cap 163M 194M 177M 148M 278M 17.95B 292M 1.98B 787M 9.81B 727M 712M 30.78B P/E 2026 *
-4.78x
P/E 2027 * 6.36x
Enterprise Value 118M 141M 128M 107M 201M 13.01B 211M 1.44B 570M 7.11B 527M 516M 22.3B EV / Sales 2026 *
5.36x
EV / Sales 2027 * 1.87x
Free-Float
55.98%
Yield 2026 *
-
Yield 2027 * -
1 day-8.45%
1 week-8.45%
Current month-12.16%
1 month-21.69%
3 months-26.14%
6 months-32.53%
Current year-37.90%
1 week 1.93
Extreme 1.93
2.16
1 month 1.93
Extreme 1.93
2.55
Current year 1.93
Extreme 1.93
3.9
1 year 1.93
Extreme 1.93
3.9
3 years 1.43
Extreme 1.4299
5.14
5 years 1.43
Extreme 1.4299
5.62
10 years 1.43
Extreme 1.4299
17.4
Manager TitleAgeSince
Chief Executive Officer 64 2026-06-10
Director of Finance/CFO 37 2021-12-31
Chief Tech/Sci/R&D Officer 45 2012-12-31
Director TitleAgeSince
Director/Board Member 70 2018-12-31
Director/Board Member 65 2021-10-28
Chairman 64 2025-06-18
Date Insider Type Main position Quantity % Market Cap. Importance
10/2/26 Other

Director

12,959 0.0127%
10/2/26 Other

Director

32,524 0.0320%
5/15/26 Sell

Founder

-10,000 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
-8.45%-8.45%-32.99%-38.87% 212M
-0.30%-6.68%+29.12%+125.42% 1,204B
+1.25%-5.35%+33.19%+80.42% 643B
+0.94%-2.99%+24.73%+106.93% 501B
-0.60%-1.95%+27.26%+67.32% 378B
+0.69%-9.50%+40.80%+30.23% 327B
+0.41%-4.70%+27.23%+51.59% 285B
+0.81%-4.08%-1.74%+32.71% 270B
-0.15%-6.45%+29.63%+64.18% 237B
-0.06%-0.98%+33.15%+118.99% 207B
Average -0.51%-5.16%+21.04%+63.89% 405B
Weighted average by Cap. +0.39%-5.21%+28.03%+87.58%

Financials

2026 *2027 *
Net sales 22M 26.21M 23.87M 20.01M 37.54M 2.43B 39.45M 268M 106M 1.33B 98.34M 96.27M 4.16B 95.92M 114M 104M 87.25M 164M 10.58B 172M 1.17B 464M 5.78B 429M 420M 18.14B
Net income -34.52M -41.14M -37.47M -31.4M -58.91M -3.81B -61.92M -420M -167M -2.08B -154M -151M -6.53B 24.54M 29.24M 26.63M 22.32M 41.88M 2.71B 44.01M 299M 119M 1.48B 110M 107M 4.64B
Net Debt -44.8M -53.38M -48.62M -40.75M -76.45M -4.94B -80.35M -545M -217M -2.7B -200M -196M -8.47B 17.1M 20.38M 18.56M 15.55M 29.18M 1.89B 30.67M 208M 82.72M 1.03B 76.45M 74.84M 3.23B
Projected Income Statement - Annual - AC Immune SA
Logo AC Immune SA
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Employees
106
Date Price Change Volume
26-11-20 US$1.950 -8.45% 298,382
26-11-19 US$2.130 +1.43% 605,419
26-11-18 US$2.100 -0.47% 80,191
26-11-17 US$2.110 +0.96% 117,137
26-11-16 US$2.090 -1.88% 99,324
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - AC Immune SA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.637CHF
Average target price
7.057CHF
Spread / Average Target
+331.20%
  1. Stock Market
  2. Stocks
  3. ACIU Stock